Dynamic immune response and its influencing factors in COVID-19 patients with non-alcoholic fatty liver disease: A cohort study

Figure 5 Impact of comorbidities on lymphocyte subsets and their percentages in coronavirus disease 2019 patients with non-alcoholic fatty liver disease: A longitudinal analysis from hospital admission to 4 weeks post-discharge. A: Lymphocyte subset counts (cells/μL); B: Lymphocyte subset percentages (%). ^aP < 0.05, 0 vs 1; ^bP < 0.05, 0 vs 2; ^cP < 0.05, 0 vs 3; ^dP < 0.05, 1 vs 2; ^eP < 0.05, 1 vs 3; ^fP < 0.05, 2 vs 3; ^gP < 0.001; ^hP < 0.05; ⁱP < 0.01. LY: Lymphocyte counts; 0: No comorbidities; 1: One comorbidity; 2: Two comorbidities; ≥ 3: Three or more comorbidities.